Effect of medroxyprogesterone versus placebo after hysteroscopic polypectomy on the clinical response and recurrence of endometrial polyp: a single-blind randomized clinical trial

开始日期2024-12-21

申办/合作机构

Hamedan University of Medical Sciences

NCT06665997

/ Not yet recruiting临床4期IIT

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females with Sickle Cell Disease

This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease.
Participants in this study will be adult women with sickle cell disease who regularly experience sickle cell pain. They will complete a 3-month "baseline "with no use of hormonal contraception, and then a 3-month follow-up after receiving an injection of Depo-Provera. Participants will complete 6 to 7 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as complete remote weekly surveys and monthly home pregnancy tests.

开始日期2024-12-01

申办/合作机构

University of Pennsylvania

[+1]

IRCT20181028041484N2

/ RecruitingN/AIIT

Comparing the Effects of Oral Caffeine and Medroxyprogesterone on Improving Respiratory Function in Traumatic Brain Injury Patients Under Mechanical Ventilation

开始日期2024-11-21

申办/合作机构-

100 项与醋酸甲羟孕酮相关的临床结果

登录后查看更多信息

100 项与醋酸甲羟孕酮相关的转化医学

登录后查看更多信息

100 项与醋酸甲羟孕酮相关的专利（医药）

登录后查看更多信息

12,774

项与醋酸甲羟孕酮相关的文献（医药）

2025-02-01·Public Health

Childhood maltreatment and its dose-response relation with non-suicidal self-injury among adolescents: The mediating role of mobile phone addiction

Article

作者: Peng, Chang ; Wang, Yan ; Zhang, Nan ; Xu, Zixuan ; Hu, Jie ; Rong, Fajuan ; Guan, Meiqi ; Yu, Yizhen ; Cheng, Junhan

OBJECTIVESThe associations between childhood maltreatment (CM) and mobile phone addiction (MPA), as well as non-suicidal self-injury (NSSI) have been extensively explored. However, the dose-response relationship between CM and NSSI remains inconsistent. Furthermore, there is limited understanding of the potential mediation effect of MPA on the relationship between CM and NSSI. This study aimed to explore the dose-response relationship between CM and NSSI and investigate the potential mediating role of MPA in this relationship.STUDY DESIGNCross-sectional study. Cross-sectional study.METHODSIn the cross-sectional study, a total of 21481 adolescents were selected using a multi-stage cluster sampling method in China. CM, MPA, and NSSI were obtained via self-reports. Data were analyzed using logistic regression models, restricted cubic spline (RCS) functions, and mediation models.RESULTSA total of 38.1 % of adolescents reported engaging in NSSI at least once. Compared with participants without CM, participants with more types of CM (cumulative childhood maltreatment, CCM) had a higher risk of NSSI (P-trend in all models <0.001). RCS further confirmed the dose-response relationships between the continuous change in CM (scores) and the risk of NSSI (P for non-linearity <0.001). Mediation analysis indicated that the relationship between CM (scores) and NSSI was mediated by MPA, and the indirect effect (β = 1.07 × 10^-3, 95 % CI: 9.62 × 10^-4, 1.19 × 10^-3) accounted for 22.23 % of the total effect.CONCLUSIONSThere was a dose-response relationship between CM and the NSSI, and the relationship was mediated by MPA. Interventions targeting MPA may reduce the risk of NSSI among adolescents who have experienced CM, particularly those with CCM.

2025-02-01·AIDS

Bone density changes in young women in Uganda using tenofovir-based HIV preexposure prophylaxis and depot medroxyprogesterone acetate contraception

Article

作者: Wyatt, Christina ; Mujugira, Andrew ; Zewdie, Kidist ; Thomas, Katherine K. ; Mugwanya, Kenneth ; Yin, Michael T. ; Badaru, Josephine ; Matovu, Flavia ; Muwonge, Timothy R. ; Morrison, Susan ; Stein, Gabrielle ; Nakyanzi, Agnes ; Bambia, Felix ; Ssebuliba, Timothy ; Heffron, Renee

Background:Injectable depot medroxyprogesterone acetate (DMPA) is the most common contraceptive choice among young women in Uganda, where HIV burden is high and HIV preexposure prophylaxis (PrEP) may be offered. For young women who choose to use both agents concurrently, it is unknown whether they will experience declines in bone mineral density (BMD) beyond those elicited by either product singly.Methods:From 2018 to 2022, we conducted a 2-year prospective study with women ages 16–25 years in Kampala, Uganda desiring pregnancy and HIV prevention. Women were provided condoms, injectable DMPA, and/or FTC/TDF, according to their choices and underwent annual dual X-ray absorptiometry (DXA) scans. We used tenofovir-diphosphate (TFV-DP) quantification in dried blood spots and DMPA injection dates to classify exposure. Linear regression models estimated the difference in percent BMD change from baseline to month 12 for women using FTC/TDF and DMPA versus women using neither product.Results:Of 499 enrolled women, discontinuation and re-starting of contraception and PrEP was common. Women consistently using neither product (n = 39) experienced BMD increases. Women with consistent use of both products during 1 year (n = 22) experienced an average BMD loss of 1.04% at lumbar spine and hip and 1.77% at femoral neck. These losses were different relative to women who used neither agent: lumbar spine −3.35% (95% CI −5.13 to −1.56%, P = 0.001), total hip −2.24% (95% CI −3.87 to −0.60%, P = 0.009), and femoral neck −1.71% (95% CI −3.73 to 0.31%, P = 0.102).Conclusion:We observed a trend for women with concurrent DMPA and FTC/TDF PrEP use to have 1–3% lower BMD than unexposed women after 12 months.

2025-02-01·Contraception

Potential effect of immediate postpartum use of injectable contraception on lactogenesis

Article

作者: Dupper, Amy C ; Keder, Lisa ; Lawley, Megan ; Gallo, Maria F. ; Schumacher, Fernanda L ; Gallo, Maria F ; Keim, Sarah A ; Schumacher, Fernanda L. ; Keim, Sarah A. ; Dupper, Amy C.

OBJECTIVESWe evaluated the effect of immediate postpartum use of depot medroxyprogesterone acetate (DMPA) on the timing of lactogenesis stage II (LS-II).STUDY DESIGNThe initial design randomly assigned adults who delivered a full-term infant in 2019-2021 to receive within 48 hours of delivery: (1) DMPA, (2) placebo injection, or (3) no injection. Due to low enrollment, we changed in 2021-2023 to a nonrandomized design using matching at recruitment for obesity and delivery method and propensity score weighting for analysis. We combined data from both designs to compare immediate postpartum DMPA use (N = 55) vs control (placebo or no injection) group (N = 95). We defined noninferiority a priori as being met if the upper bound of a two-sided 95% CI for mean difference in time to LS-II between groups was <6 hours.RESULTSThe unweighted mean time to LS-II was 57.8 hours in the DMPA group (SD, 29.4) and 64.1 hours in the control group (SD, 36.1). Using propensity score weighting to make the groups comparable with respect to age, race, delivery method, and previous live births, the mean time to LS-II was 5.5 hours shorter (95% CI, -16.4, 5.5) for women in the DMPA relative to control group.CONCLUSIONSWe found no evidence that DMPA use inhibits the onset of LS-II. Findings support immediate postpartum DMPA initiation among those intending to engage in human milk feeding.IMPLICATIONSA controlled trial (N = 150) did not detect any difference in time to lactogenesis stage II ("milk let-down") between injectable contraception use within the first 48 hours postpartum and those without this exposure.

项与醋酸甲羟孕酮相关的新闻（医药）

2025-01-19

·药筛

两性霉素B脂质体国产第4家，河南中帅右哌甲酯缓释胶囊首家上市 | 仿制药周报（1.12-1.19）

统计每周仿制药一致性评价申报、上市申请（1.12-1.19） 1、仿制药上市申请获批药品名称企业名称分类受理号氨氯地平贝那普利胶囊河北龙海药业有限公司3CYHS2301852氨溴特罗口服溶液南京创迪生物技术有限公司;江苏贝佳制药有限公司3CYHS2302950奥拉帕利片Natco Pharma Limited5.2JYHS2300075奥拉帕利片Natco Pharma Limited5.2JYHS2300074奥美拉唑碳酸氢钠干混悬剂湖北邦泽医药有限公司;哈尔滨美君制药有限公司3CYHS2301623奥美沙坦酯氨氯地平片裕松源药业有限公司4CYHS2404050贝前列素钠片江西科睿药业有限公司4CYHS2303507苯磺酸氨氯地平片广州一品红制药有限公司4CYHS2303192苯磺酸氨氯地平片广州一品红制药有限公司4CYHS2303193吡拉西坦注射液西安达莫制药有限公司;山东华鲁制药有限公司3CYHS2400403玻璃酸钠滴眼液辅必成（上海）医药科技有限公司;浙江赛默制药有限公司4CYHS2400844达比加群酯胶囊浙江诺得药业有限公司4CYHS2303164达比加群酯胶囊浙江诺得药业有限公司4CYHS2303162达比加群酯胶囊浙江诺得药业有限公司4CYHS2303163地夸磷索钠滴眼液山东诺明康药物研究院有限公司;山东光明药业有限公司4CYHS2302729地诺孕素片南通联亚药业股份有限公司4CYHS2301847二羟丙茶碱注射液河北千康医药科技有限责任公司;青岛金峰制药有限公司3CYHS2302021非那雄胺片乐泰药业有限公司;南京海纳制药有限公司4CYHS2302057非那雄胺片乐泰药业有限公司;南京海纳制药有限公司4CYHS2302056复方氨基酸注射液(18AA-Ⅸ)四川科伦药业股份有限公司4CYHS2302546复方甘草酸苷片东阳祥昇医药科技有限公司;浙江北生药业汉生制药有限公司4CYHS2301720富马酸福莫特罗吸入溶液南京力成药业有限公司4CYHS2303034富马酸福莫特罗吸入溶液长风药业股份有限公司4CYHS2302621腹膜透析液(艾考糊精)芜湖道润药业有限责任公司4CYHS2401530钆喷酸葡胺注射液四川国瑞药业有限责任公司4CYHS2301898甲苯磺酸艾多沙班片齐鲁制药有限公司4CYHS2302691甲苯磺酸艾多沙班片齐鲁制药有限公司4CYHS2302693甲苯磺酸艾多沙班片齐鲁制药有限公司4CYHS2302692甲钴胺注射液广州一品红制药有限公司;河北凯威制药有限责任公司4CYHS2303000甲磺酸仑伐替尼胶囊吉林敖东洮南药业股份有限公司4CYHS2301718甲磺酸仑伐替尼胶囊吉林敖东洮南药业股份有限公司4CYHS2301719间苯三酚注射液江苏悦兴药业有限公司4CYHS2302047酒石酸溴莫尼定滴眼液广东众生药业股份有限公司4CYHS2303512磷酸奥司他韦胶囊福建省闽东力捷迅药业股份有限公司4CYHS2400923磷酸奥司他韦胶囊植恩生物技术股份有限公司4CYHS2400901硫酸羟氯喹片福建广生堂药业股份有限公司4CYHS2303516硫酸特布他林雾化吸入用溶液浙江金华康恩贝生物制药有限公司4CYHS2301885氯雷他定糖浆南通广承制药有限公司;江苏广承药业有限公司4CYHS2302830氯沙坦钾氢氯噻嗪片裕松源药业有限公司4CYHS2404128罗沙司他胶囊北京福元医药股份有限公司4CYHS2302941罗沙司他胶囊北京福元医药股份有限公司4CYHS2302942罗沙司他胶囊广州康臣药业有限公司;成都倍特药业股份有限公司4CYHS2302564罗沙司他胶囊哈尔滨三联药业股份有限公司;兰西哈三联制药有限公司4CYHS2302026罗沙司他胶囊哈尔滨三联药业股份有限公司;兰西哈三联制药有限公司4CYHS2302025马来酸阿伐曲泊帕片湖南明瑞制药股份有限公司4CYHS2302991马来酸阿伐曲泊帕片瑞阳制药股份有限公司4CYHS2302556马来酸咪达唑仑片宜昌人福药业有限责任公司4CYHS2302782玛巴洛沙韦片郑州泰丰制药有限公司4CYHS2302877尼可地尔片浙江赛默制药有限公司4CYHS2303503帕拉米韦注射液长春澜江医药科技有限公司;山东新时代药业有限公司3CYHS2302932普瑞巴林口服溶液常州四药制药有限公司3CYHS2301334乳果糖口服溶液安徽美来药业股份有限公司;安徽永生堂药业有限责任公司4CYHS2302196沙库巴曲缬沙坦钠片江苏德源药业股份有限公司4CYHS2303296羧甲司坦口服溶液海南斯达制药有限公司3CYHS2300946托吡酯片海南日中天制药有限公司4CYHS2301074吸入用布地奈德混悬液浙江高跖医药科技股份有限公司;浙江赛默制药有限公司4CYHS2302457西格列汀二甲双胍片(Ⅱ)江苏康缘药业股份有限公司4CYHS2302127盐酸氮卓斯汀滴眼液浙江视方极医药科技有限公司;浙江赛默制药有限公司4CYHS2303213盐酸氮卓斯汀滴眼液浙江视方极医药科技有限公司;浙江赛默制药有限公司4CYHS2302677盐酸莫西沙星片河北天成药业股份有限公司4CYHS2302521盐酸伊托必利片裕松源药业有限公司4CYHS2404103盐酸右哌甲酯缓释胶囊河南中帅药业有限公司3CYHS2303628伊布替尼胶囊江西科睿药业有限公司4CYHS2302871异丙托溴铵雾化吸入溶液浙江金华康恩贝生物制药有限公司4CYHS2302237注射用两性霉素B脂质体江西艾施特制药有限公司4CYHS2301518注射用替考拉宁重庆药友制药有限责任公司4CYHS2301539注射用紫杉醇(白蛋白结合型)河北天成药业股份有限公司;河北道恩药业有限公司4CYHS2303294 注：灰色字体部分受理号结论为不批准。 2、一致性评补充申请获批药品名称企业名称受理号硫酸阿托品注射液湖北美林药业有限公司;天津金耀药业有限公司CYHB2350793马来酸曲美布汀片信合援生制药股份有限公司CYHB2350919碳酸氢钠注射液河北天成药业股份有限公司CYHB2350816碳酸氢钠注射液河北天成药业股份有限公司CYHB2350815碳酸氢钠注射液湖南科伦制药有限公司CYHB2350800碳酸氢钠注射液湖南科伦制药有限公司CYHB2350799依达拉奉注射液北京四环制药有限公司;吉林四环制药有限公司CYHB2350087依达拉奉注射液华润双鹤药业股份有限公司CYHB2250464吲达帕胺片上海迪冉郸城制药有限公司CYHB2450115注射用奥美拉唑钠常州四药制药有限公司CYHB2350953注射用头孢唑肟钠汕头金石粉针剂有限公司CYHB2350958注射用维库溴铵海南斯达制药有限公司CYHB2350684 注：灰色字体部分受理号结论为不批准。 3、新增仿制药上市申请药品名称企业名称分类受理号阿司匹林肠溶片华中药业股份有限公司4CYHS2500315阿昔莫司胶囊天津掌心医药科技有限公司;淄博万杰制药有限公司4CYHS2500359艾拉莫德片宁夏康亚药业股份有限公司4CYHS2500290艾普拉唑肠溶片北京福元医药股份有限公司4CYHS2500267氨酚羟考酮片河北奥星集团药业有限公司3CYHS2500297氨溴特罗口服溶液江苏神华药业有限公司;安徽永生堂药业有限责任公司3CYHS2500307苯溴马隆片沐源（安徽）药业有限公司;华益药业科技（安徽）有限公司3CYHS2500325苯溴马隆片广州一品红制药有限公司3CYHS2500326比拉斯汀片江苏联环药业股份有限公司4CYHS2500324比索洛尔氨氯地平片海南广升誉制药有限公司;华益泰康药业股份有限公司4CYHS2500343吡拉西坦注射液石药银湖制药有限公司3CYHS2500336别嘌醇片安徽圣鹰药业有限公司3CYHS2500282玻璃酸钠滴眼液修正药业集团长春高新制药有限公司4CYHS2500306布美他尼注射液浙江赛默制药有限公司3CYHS2500331布美他尼注射液浙江赛默制药有限公司3CYHS2500330布瑞哌唑片浙江华义制药有限公司4CYHS2500280布瑞哌唑片浙江华义制药有限公司4CYHS2500281草酸艾司西酞普兰片山东普瑞曼药业有限公司4CYHS2500272蛋白琥珀酸铁口服溶液国药控股星鲨制药（厦门）有限公司4CYHS2500266地屈孕酮片M/s MANKIND PHARMA LIMITED5.2JYHS2500004碘佛醇注射液山东齐都药业有限公司;博瑞制药（苏州）有限公司4CYHS2500275二十碳五烯酸乙酯软胶囊北京诚济制药股份有限公司;人福普克药业（武汉）有限公司4CYHS2500358二十碳五烯酸乙酯软胶囊浙江创新生物有限公司4CYHS2500312氟脲嘧啶注射液海南倍特药业有限公司3CYHS2500316氟脲嘧啶注射液海南倍特药业有限公司3CYHS2500317复方氨基酸(15)双肽(2)注射液成都诺和晟鸿生物制药有限公司;四川美大康佳乐药业有限公司4CYHS2500268复方氨基酸(15)双肽(2)注射液成都诺和晟鸿生物制药有限公司;四川美大康佳乐药业有限公司4CYHS2500269富马酸伏诺拉生片浙江华海药业股份有限公司4CYHS2500278富马酸伏诺拉生片浙江华海药业股份有限公司4CYHS2500277富马酸酮替芬滴眼液石家庄格瑞药业有限公司3CYHS2500328富马酸酮替芬滴眼液石家庄格瑞药业有限公司3CYHS2500329富马酸依美斯汀滴眼液广州大光制药有限公司4CYHS2500349枸橼酸西地那非口崩片东莞松山湖美健生物技术有限公司;东莞市金美济药业有限公司4CYHS2500293枸橼酸西地那非口崩片南京康川济医药科技有限公司;浙江四维医药科技有限公司4CYHS2500283己酮可可碱缓释片浙江普洛康裕制药有限公司3CYHS2500327己酮可可碱缓释片福建海西新药创制股份有限公司;广东安诺药业股份有限公司3CYHS2500310甲硝唑阴道凝胶杭州上禾健康科技有限公司;浙江鼎泰药业股份有限公司3CYHS2500352精氨酸布洛芬片海南赛立克药业有限公司4CYHS2500294酒石酸阿福特罗雾化吸入溶液江苏长泰药业股份有限公司3CYHS2500279聚多卡醇注射液海南合瑞制药股份有限公司4CYHS2500318聚多卡醇注射液海南合瑞制药股份有限公司4CYHS2500319聚乙二醇钠钾散湖北唯森制药有限公司4CYHS2500334聚乙二醇钠钾散郑州泰丰制药有限公司4CYHS2500338聚乙烯醇滴眼液南京恒道医药科技股份有限公司;江苏大红鹰恒顺药业有限公司4CYHS2500321糠酸莫米松乳膏江苏知原药业股份有限公司4CYHS2500288利丙双卡因乳膏江苏吴中医药集团有限公司苏州制药厂;浙江赛默制药有限公司4CYHS2500322硫酸氢氯吡格雷片华泰民康（沈阳）科技有限公司;苏州特瑞药业股份有限公司4CYHS2500311硫酸沙丁胺醇口服溶液辽宁海一制药有限公司3CYHS2500292硫酸特布他林雾化吸入用溶液复星医药（徐州）有限公司4CYHS2500351硫糖铝片新乡市常乐制药有限责任公司3CYHS2500284柳氮磺吡啶口服混悬液上海信谊金朱药业有限公司3CYHS2500341罗沙司他胶囊华北制药金坦生物技术股份有限公司;华北制药股份有限公司4CYHS2500303罗沙司他胶囊华北制药金坦生物技术股份有限公司;华北制药股份有限公司4CYHS2500302洛索洛芬钠贴剂前沿生物药业（南京）股份有限公司;湖南派格兰药业有限公司4CYHS2500354洛索洛芬钠贴剂前沿生物药业（南京）股份有限公司;湖南派格兰药业有限公司4CYHS2500355吗替麦考酚酯干混悬剂昆明贝克诺顿制药有限公司3CYHS2500271美索巴莫片石家庄四药有限公司3CYHS2500273蒙脱石混悬液合肥远志医药科技开发有限公司;安徽永生堂药业有限责任公司4CYHS2500320米库氯铵注射液四川美大康佳乐药业有限公司4CYHS2500332米库氯铵注射液江西远超医药科技有限公司;朗天药业（湖北）有限公司4CYHS2500340米库氯铵注射液四川美大康佳乐药业有限公司4CYHS2500333米库氯铵注射液江西远超医药科技有限公司;朗天药业（湖北）有限公司4CYHS2500339帕拉米韦氯化钠注射液湖南九维生物医药有限公司;湖南金健药业有限责任公司4CYHS2500309帕拉米韦氯化钠注射液湖南九维生物医药有限公司;湖南金健药业有限责任公司4CYHS2500308培哚普利氨氯地平片(Ⅰ)杭州和泽坤元药业有限公司;山西同达药业有限公司4CYHS2500289双醋瑞因胶囊江苏永安制药有限公司4CYHS2500345双氯芬酸二乙胺乳胶剂福建品腾药业有限公司;江苏知原药业股份有限公司4CYHS2500270碳酸氢钠注射液江西泰吉立生物医药科技有限公司;浙江赛默制药有限公司3CYHS2500295碳酸氢钠注射液江西泰吉立生物医药科技有限公司;浙江赛默制药有限公司3CYHS2500296维生素B12注射液南京赛瑞谱顿制药有限公司;山东新时代药业有限公司3CYHS2500265吸入用乙酰半胱氨酸溶液重庆莱美药业股份有限公司4CYHS2500291西格列汀二甲双胍缓释片南京易亨制药有限公司3CYHS2500350西格列汀二甲双胍缓释片华中药业股份有限公司3CYHS2500276腺苷钴胺胶囊合肥康惠医药技术有限公司;上海海虹实业（集团）巢湖今辰药业有限公司3CYHS2500313盐酸二甲双胍片石家庄四药有限公司4CYHS2500286盐酸二甲双胍片石家庄四药有限公司4CYHS2500287盐酸非索非那定干混悬剂桂林华信制药有限公司3CYHS2500300盐酸非索非那定干混悬剂桂林华信制药有限公司3CYHS2500298盐酸美金刚口服溶液常州四药制药有限公司3CYHS2500337盐酸纳美芬注射液浙江赛默制药有限公司3CYHS2500353盐酸异丙肾上腺素注射液海南倍特药业有限公司3CYHS2500305盐酸异丙肾上腺素注射液海南倍特药业有限公司3CYHS2500304叶酸片江苏贝佳制药有限公司3CYHS2500342脂肪乳氨基酸(17)葡萄糖(19%)注射液四川太平洋药业有限责任公司4CYHS2500274注射用磷丙泊酚二钠河北科源药业有限公司;仁合益康汇泽药业河北有限公司4CYHS2500285注射用磷酸特地唑胺浙江尖峰药业有限公司4CYHS2500344注射用磷酸特地唑胺珠海优润医药科技有限公司;珠海同源药业有限公司4CYHS2500314注射用硫酸艾沙康唑桂林南药股份有限公司;苏州二叶制药有限公司4CYHS2500348注射用硫酸艾沙康唑湖南赛隆药业（长沙）有限公司;湖南赛隆药业有限公司4CYHS2500335注射用培美曲塞二钠湖南赛隆药业（长沙）有限公司;山西普德药业有限公司4CYHS2500347注射用培美曲塞二钠湖南赛隆药业（长沙）有限公司;山西普德药业有限公司4CYHS2500346注射用亚胺培南西司他丁钠珠海优润医药科技有限公司;珠海联邦制药股份有限公司4CYHS2500301注射用亚胺培南西司他丁钠珠海优润医药科技有限公司;珠海联邦制药股份有限公司4CYHS2500299唑来膦酸注射液四川太平洋药业有限责任公司3CYHS2500323ω-3鱼油中/长链脂肪乳注射液贝朗医疗（苏州）有限公司4CYHS2500356ω-3鱼油中/长链脂肪乳注射液贝朗医疗（苏州）有限公司4CYHS2500357 4、新增一致性评价补充申报药品名称企业名称受理号醋酸甲羟孕酮片浙江仙琚制药股份有限公司CYHB2550051醋酸甲羟孕酮片浙江仙琚制药股份有限公司CYHB2550050丁溴东莨菪碱注射液中孚药业股份有限公司CYHB2550053瑞巴派特片浙江大冢制药有限公司CYHB2550052盐酸甲氧氯普胺注射液成都倍特药业股份有限公司CYHB2550049注射用头孢他啶深圳信立泰药业股份有限公司CYHB2550048注射用头孢他啶深圳信立泰药业股份有限公司CYHB2550047 数据来源：摩熵医药

一致性评价上市批准专利到期

2025-01-15

·PRNewswire

Depo-Provera Brain Tumor Litigation: All-Female Legal Team Takes on Devastating Female Health Issue

MINNEAPOLIS, Jan. 15, 2025 /PRNewswire/ -- National personal injury law firm Pritzker Hageman has assembled an all-female legal team to pursue litigation on behalf of women who developed meningioma tumors after using Depo-Provera birth control injections. Attorneys Alicia Penner and Morgan Vanden Heuvel are currently representing a South Dakota woman who developed multiple meningiomas following years of receiving Depo-Provera injections. Penner and Vanden Heuvel are urging women who received at least two Depo-Provera injections and were later diagnosed with a meningioma to contact them. Raising Awareness and Seeking Justice Penner and Vanden Heuvel stated that victims may be entitled to compensation for medical expenses, including surgeries and radiation therapy, as well as lost income, pain and suffering, and emotional distress related to symptoms such as paralysis, vision loss, seizures, cognitive decline, and debilitating headaches. Their client, who received Depo-Provera injections as prescribed, has suffered significant health consequences, including multiple surgeries, radiation treatment, vision loss, and other tumor-related impairments. Pritzker Hageman's Depo-Provera lawsuit team is committed to raising awareness among women across the country about the potential risks. "Depo-Shots" Linked to Tumor Growth Compelling scientific research shows that the extremely high doses of the synthetic progestin hormone in Depo-Provera can stimulate the growth of meningiomas. Depo-Provera was approved for contraceptive use in the United States in 1992, but studies going back to 1983 suggested that levels of synthetic progestin hormones found in Depo-Provera can bind to receptors on meningiomas, accelerating their growth. While these tumors are often called "benign," their location means they can compress the brain and spinal cord and lead to severe complications. Pritzker Hageman's Depo-Provera litigation aims to expose the fact that Pfizer and other companies failed to adequately warn women of the meningioma risk. "We want women to have awareness that users of Depo-Provera are at risk," Vanden Heuvel stated. "The longer you take it, the more likely it is that you would develop a brain tumor," Penner added. The potential number of women affected is substantial. In 2020, over 2 million prescriptions for Depo-Provera were written in the U.S. About Pritzker Hageman Pritzker Hageman is a nationally renowned law firm with a proven track record of successfully representing clients in complex personal injury and product liability cases. The firm is committed to holding corporations accountable for negligence and securing justice for those who have been harmed. Contact Alicia Penner 1-888-377-8900 [email protected] Morgan Vanden Heuvel 1-888-377-8900 [email protected] SOURCE Pritzker Hageman, P.A. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准放射疗法专利侵权

2024-12-13

·拜尔迪生物

近岸 | 类器官培养关键细胞因子—FGF-4

关于FGF-4 成纤维细胞生长因子（Fibroblast Growth Factors，FGFs）是一类普遍存在于哺乳动物体内的促细胞分裂肝素结合蛋白，其与受体FGFR均在种间高度保守。FGFs可诱导调节细胞增殖分化、胚胎发育、血管再生、损伤修复、肿瘤发生等多个生理进程[1]。近岸类器官课堂：类器官培养关键细胞因子之FGF家族 FGF-4隶属FGF旁分泌亚家族，最初从人胃肿瘤中分离，正常情况下在成人体内少量表达于十二指肠、回肠和结肠中以维持肠干细胞稳态[2]。FGF-4通过硫酸乙酰肝素依赖性路径传递信号，可激活配体FGFR（与FGFR4结合特异性最强）启动损伤修复、器官再生和代谢调控[3]。在人胚胎发育过程中，FGF-4助力干细胞的自我更新与胚胎磨牙芽的发育。 FGF-4与类器官培养 1 肠道类器官 2014年，研究人员使用iPSC来源的类器官首度在体外构建了3D人体肠道组织模型。实验发现，生长因子FGF-4和WNT-3a可促进CDX2+后肠内胚层特异性模式化，并产生三维球状体[4]。2015年的一篇论文则提出，FGF-4在肠道类器官培养中的主要作用可能是抑制hPSC向肝谱系的分化[5]。在2017年和2018年相继发表的两项研究指出，类器官在短期暴露于FGF-4和CHIR 99021（一种Wnt/β-catenin信号通路激活剂）的培养条件下，更倾向于形成十二指肠类器官；而长期暴露则引导其向回肠组织的基因表达模式发展。值得注意的是，当完全缺乏CHIR 99021和FGF-4的添加时，体外实验中未能观察到后肠球状体的形成[6,7]。图1 从iPSC体外分化肠道类器官的示意图[4] 2 胃类器官 2021年发表于Nature Protocol的文章介绍了使用hPSC产生功能性胃细胞的方法。该实验方法使用Activin A将hPSC分化成定形内胚层（DE），然后添加FGF 4与CHIR 99021产生自由漂浮的3D前肠后部球状体，并最终形成胃窦和胃底类器官[7]。图2 hPSC诱导产生胃窦和胃底类器官的路径[7] 3 肺类器官为了应对SARS-CoV-2等呼吸道疾病，体外肺部3D模型一直是研究的重点。来自美国密歇根大学医学院的研究团队通过添加Noggin、SB、FGF-4、CHIR99021，从hPSC开发出人肺类器官（HLO）[8]。该研究得到的HLO由肺的上皮和间充质隔室组成，具有上气道样上皮以及被平滑肌和肌成纤维细胞包围的基底细胞。与此同时，HLO还拥有未成熟纤毛细胞和肺泡样结构域。 2021年，发表于Nature的一篇文章使用FGF-4+CHIR 99021从hPSC获得肺类器官，并检测到类器官中肺泡II型细胞标志物的表达[9]。使用SARS-CoV-2感染肺类器官，观测到趋化因子被高度诱导，与COVID-19患者感染症状类似。基于肺类器官模型，研究者对FDA批准的药物进行了高通量筛选，发现SARS-CoV-2感染抑制剂伊马替尼、麦考酚酸（MPA）和盐酸奎纳克林（QNHC）等，为COVID-19治疗提供了新思路。图3 肺类器官不同培养阶段的代表性图像[10] 4 肝脏类器官脂肪型肝炎由多种因素导致，其中非酒精性脂肪肝（NAFLD）以及非酒精性脂肪性肝炎（NASH）的全球患病率及病死率非常高。为了深入探究脂肪性肝炎基因型-表型关联及其与糖类代谢之间的联系，2022年，发表于Cell上的一篇研究通过添加FGF-4和CHIR 99021，构建了单纯性脂肪变性和脂肪性肝炎的类器官模型[11]。实验发现葡萄糖激酶调节蛋白（GCKR）-rs1260326-T等位基因仅在同时患有糖尿病的前提下加重NASH，为糖尿病-NAFLD/NASH的治疗奠定了分子基础。 5 心脏类器官 FGF及其受体FGR1在心脏发育中发挥至关重要的作用，如FGF-4-FGFR1通路调节心肌细胞与其他细胞之间的增殖平衡以确保心室结构正确。为了探究心脏发育机制，2020年的一篇研究探索了体外心脏类器官模型建立的路径[12]。向来自小鼠胚胎干细胞的胚状体添加外源FGF-4后，成功诱导初始心肌细胞的增殖和第八天心室的形成。与家族内的其他因子比较，FGF-4的诱导效率最高（两次实验中，FGF-4为88%和78%，FGF10为42%和25%）。最终成功获得具有心肌细胞超微结构特性的心脏类器官，并表达相关转录因子与结构基因，为体外心脏药物筛选、诊疗等提供了新的平台。图5 心脏类器官不同培养阶段的代表性图像[12] 近岸蛋白提供高活性，高批间一致性的重组FGF-4蛋白，并经过类器官培养验证，让您的类器官培养更可控！产品数据高活性 Measured in a cell proliferation assay using MCF7 Human breast cancer cells.The ED50 for this effect is 2-20 ng/ml. 高批间一致性 Three independent lots were tested for activity and plotted on the same graph to show lot-to-lot consistency of FGF-4(Cat#CR08). 类器官培养验证 Human intestinal organoids (ipsc source) were cultured with Activin A(Cat#C687) , BMP-4(Cat#CR93) , EGF (Cat#C029) , Wnt3a (Cat#C22R), Noggin (Cat#C028), R-spondin 1 (Cat#CX83) and FGF-4 (Cat#CR08) . The organoids showed good morphology. 相关产品：类器官培养类型相关因子胃类器官 Activin A、BMP-4、EGF、FGF-4、FGF-10、Noggin、R-spondin 1、Wnt3a 肠类器官 Activin A、BMP-4、EGF、FGF-4、Noggin、R-spondin 1、Wnt3a 肝类器官 Activin A、BMP-4、BMP-7、FGF-7、FGF-10、FGF-19、HGF、OSM、R-Spondin 1 肺类器官 Activin A、FGF-4、FGF-7、FGF-10、Noggin、SHH、Wnt3a 前列腺类器官 EGF、FGF-10、Noggin、R-spondin 1、Wnt-3a 脑类器官 BDNF、EGF、FGF basic、GDNF、NT-3 内耳类器官 BMP-4、FGF basic 视网膜类器官 SHH、Wnt-3a 乳腺类器官 EGF、FGF basic、FGF-7、FGF-10、Heregulinβ-1、Noggin、R-Spondin 1、R-Spondin 3、Wnt-3a 肾脏类器官 BMP-2、BMP-4、BMP-7、FGF basic、FGF-9、Activin A、FGF-7、GDNF、R-Spondin 1 心脏类器官 Activin A、BMP-4、FGF basic、TGF-beta 1、Transferrin 血管类器官 BMP-4、FGF basic、VEGF 参考文献 [1]Xie, Yangli et al. “FGF/FGFR signaling in health and disease.” Signal transduction and targeted therapy vol. 5,1 181. 2 Sep. 2020, doi:10.1038/s41392-020-00222-7 [2]Tian, Haoyu et al. “Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges.” International journal of molecular sciences vol. 24,5 4583. 26 Feb. 2023, doi:10.3390/ijms24054583 [3]Morita, Hideaki, and Masaaki Hoshiga. “Fibroblast Growth Factors in Cardiovascular Disease.” Journal of atherosclerosis and thrombosis vol. 31,11 (2024): 1496-1511. doi:10.5551/jat.RV22025 [4]McCracken, Kyle W et al. “Generating human intestinal tissue from pluripotent stem cells in vitro.”Nature protocolsvol. 6,12 1920-8. 10 Nov. 2011, doi:10.1038/nprot.2011.410 [5]Tamminen, Kaisa et al. “Intestinal Commitment and Maturation of Human Pluripotent Stem Cells Is Independent of Exogenous FGF-4 and R-spondin1.”PloS onevol. 10,7 e0134551. 31 Jul. 2015, doi:10.1371/journal.pone.0134551 [6]Tsai, Yu-Hwai et al. “In vitropatterning of pluripotent stem cell-derived intestine recapitulatesin vivohuman development.”Development (Cambridge, England)vol. 144,6 (2017): 1045-1055. doi:10.1242/dev.13845 [7]Zhang, Ran-Ran et al. “Human iPSC-Derived Posterior Gut Progenitors Are Expandable and Capable of Forming Gut and Liver Organoids.” Stem cell reports vol. 10,3 (2018): 780-793. doi:10.1016/j.stemcr.2018.01.006 [8]Dye, Briana R et al. “In vitro generation of human pluripotent stem cell derived lung organoids.” eLife vol. 4 e05098. 24 Mar. 2015, doi:10.7554/eLife.05098 [9]Han, Yuling et al. “Identification of SARS-CoV-2 inhibitors using lung and colonic organoids.”Naturevol. 589,7841 (2021): 270-275. doi:10.1038/s41586-020-2901-9 [10]Pei, Rongjuan et al. “Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection.”Protein & cellvol. 12,9 (2021): 717-733. doi:10.1007/s13238-020-00811-w [11]Kimura, Masaki et al. “En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH.”Cellvol. 185,22 (2022): 4216-4232.e16. doi:10.1016/j.cell.2022.09.031 [12]Lee, Jiyoung et al. “In vitro generation of functional murine heart organoids via FGF-4 and extracellular matrix.” Nature communications vol. 11,1 4283. 3 Sep. 2020, doi:10.1038/s41467-020-18031-5 上下滑动查看更多北京拜尔迪是近岸蛋白的授权代理商，更多产品，敬请咨询！

临床研究临床结果

100 项与醋酸甲羟孕酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00951	醋酸甲羟孕酮	L02AB02 G03AC06 G03DA02	DB00603

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
抑制排卵	日本	Kyowa Kirin Co., Ltd.	2022-03-11
疼痛	美国	Pfizer Inc.	2020-12-04
避孕	美国	Pfizer Inc.	2004-12-17
怀孕	美国	Pfizer Inc.	1992-10-29
乳腺癌	中国	西安利君制药有限责任公司	1982-01-01
子宫内膜癌	中国	西安利君制药有限责任公司	1982-01-01
前列腺癌	中国	西安利君制药有限责任公司	1982-01-01
肾细胞癌	中国	西安利君制药有限责任公司	1982-01-01
习惯性流产	日本	Pfizer Japan, Inc.	1963-01-25
先兆流产	日本	Pfizer Japan, Inc.	1963-01-25
月经过少	日本	Pfizer Japan, Inc.	1963-01-25
不孕	日本	Pfizer Japan, Inc.	1963-01-25
月经过多	日本	Pfizer Japan, Inc.	1963-01-25
月经紊乱	日本	Pfizer Japan, Inc.	1963-01-25
闭经	美国	Pfizer Inc.	1959-06-18
子宫内膜增生	美国	Pfizer Inc.	1959-06-18
子宫不规则出血	美国	Pfizer Inc.	1959-06-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
特应性皮炎	临床1期	中国	天津药物研究院药业有限责任公司	2019-12-11
湿疹	临床1期	中国	天津药物研究院药业有限责任公司	2019-12-11
神经性皮炎	临床1期	中国	天津药物研究院药业有限责任公司	2019-12-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02550067 (ECHO, Pubmed \| BMC Womens Health) 人工标引	N/A	避孕	398	Depot medroxyprogesterone acetate (DMPA-IM)	(蓋繭餘鹽糧繭憲鏇獵憲) = 襯憲餘鹹廠鹽網膚築獵淵繭製網構鬱顧積鏇繭 (鑰淵選獵鹹憲繭夢獵鏇 ) 更多	积极	2024-03-08
				copper intrauterine device	(蓋繭餘鹽糧繭憲鏇獵憲) = 鏇鹹鑰遞壓築繭艱繭積淵繭製網構鬱顧積鏇繭 (鑰淵選獵鹹憲繭夢獵鏇 ) 更多
NCT02550067 (Pubmed \| Clin Infect Dis)	N/A	单纯疱疹	4,062	Depot medroxyprogesterone acetate (DMPA-IM)	糧襯廠鏇顧築鏇壓鬱鬱(衊膚獵憲齋壓獵憲觸鹹) = 壓遞獵製廠遞網餘膚鑰鹽製醖觸選廠膚範範蓋 (積壓鹽鏇鹽壓窪襯積憲 )	-	2022-09-10
				Levonorgestrel (LNG) implant	糧襯廠鏇顧築鏇壓鬱鬱(衊膚獵憲齋壓獵憲觸鹹) = 鹽鹽願襯廠餘鑰憲蓋繭鹽製醖觸選廠膚範範蓋 (積壓鹽鏇鹽壓窪襯積憲 )
NCT02122198 (CTgov)	N/A	认知功能障碍 \| 内皮功能障碍 \| 执行功能受损	17	Placebo (Placebo)	鬱醖廠醖繭壓製製繭遞(觸艱範繭願積範餘艱構) = 鬱壓範觸淵選衊窪襯壓壓積鹹醖網廠齋構鏇夢 (窪衊選鑰簾鏇衊繭糧鬱, 獵淵襯製範夢鹽範糧廠 ~ 齋襯觸襯製窪獵積艱淵) 更多	-	2022-01-10
				Medroxyprogesterone+Leuprolide acetate+Estradiol (GnRH Agonist)	鬱醖廠醖繭壓製製繭遞(觸艱範繭願積範餘艱構) = 餘鬱壓獵選窪積構築淵壓積鹹醖網廠齋構鏇夢 (窪衊選鑰簾鏇衊繭糧鬱, 襯廠積簾觸範夢製獵願 ~ 糧淵鏇膚憲鏇製範範顧) 更多
NCT03018249 (CTgov)	早期临床1期	子宫内膜样腺癌	50	Medroxyprogesterone Acetate (Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA)	鬱蓋憲築鬱糧積顧衊齋(鹽構襯觸簾積範獵醖襯) = 築築簾製醖艱遞餘網餘鬱艱鹹糧鹹襯鹽糧繭蓋 (製齋艱齋艱醖淵築夢膚, 鑰觸餘廠獵夢鏇願淵廠 ~ 網鬱廠衊觸鑰遞衊齋觸) 更多	-	2021-06-02
				Medroxyprogesterone Acetate+Entinostat+MPA (Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat)	鬱蓋憲築鬱糧積顧衊齋(鹽構襯觸簾積範獵醖襯) = 製齋窪築夢範窪鑰壓構鬱艱鹹糧鹹襯鹽糧繭蓋 (製齋艱齋艱醖淵築夢膚, 獵淵餘艱淵願憲顧鬱範 ~ 襯觸鏇鏇齋醖壓範顧餘) 更多
NCT02550067 (ECHO trial, IAS2021)	N/A	阴道毛滴虫致泌尿生殖道感染 \| 生殖器支原体感染	458	DMPA-IM	鏇艱餘膚齋鏇繭構膚憲(築艱願蓋窪遞構鬱淵遞) = 遞簾選遞顧鬱觸夢製鑰鹽鹹築艱襯顧壓淵願構 (憲壓積製選壓選鬱觸鏇 ) 更多	-	2021-01-01
				Copper IUD	糧齋醖鬱鹹鑰夢膚衊窪(選鬱獵鏇齋蓋夢廠醖鹽) = 繭鹹繭淵獵積蓋獵蓋醖淵網淵選齋鹹築窪鏇觸 (選糧夢襯簾廠艱鏇壓憲 )
NCT00997893 (RISE, CTgov)	临床2期	绝经期综合征 \| 潮热	96	Soy Placebo+Medroxyprogesterone Acetate (MPA)+Estradiol (Estradiol/Medroxyprogesterone Acetate)	鏇構餘簾襯簾鬱襯餘範(範壓繭簾蓋積鹽蓋蓋鑰) = 壓網餘壓鹹窪網構衊範觸選膚窪憲夢構壓顧鹽 (淵鬱鹽艱齋觸鹽築願範, 願廠蓋窪鏇製憲糧顧鹹 ~ 糧壓衊遞艱繭廠壓範簾) 更多	-	2020-12-07
				Soy Placebo (Placebo)	鏇構餘簾襯簾鬱襯餘範(範壓繭簾蓋積鹽蓋蓋鑰) = 選鏇齋願鹽糧艱鏇糧觸觸選膚窪憲夢構壓顧鹽 (淵鬱鹽艱齋觸鹽築願範, 遞廠廠遞鬱鬱襯鹹繭淵 ~ 繭鹹簾網構夢願膚衊鏇) 更多
NCT02357368 (CTgov)	临床4期	HIV感染 \| 避孕	59	Depot medroxyprogesterone acetate (DMPA) (Depot Medroxyprogesterone Acetate (DMPA))	鬱積夢襯壓鏇窪窪築築(糧餘獵窪壓網憲餘膚範) = 淵願鹹廠簾壓餘鏇餘構夢網鹹遞齋遞窪觸壓鏇 (蓋繭鑰製獵衊積遞選觸, 餘觸鹹窪蓋蓋遞網廠糧 ~ 糧鏇壓顧願壓網鑰齋鏇) 更多	-	2020-11-18
				Levonorgestrel intrauterine device (Lng-IUD) (Levonorgestrel Intrauterine Device (Lng-IUD))	鬱積夢襯壓鏇窪窪築築(糧餘獵窪壓網憲餘膚範) = 願夢窪憲蓋鹹願選鏇窪夢網鹹遞齋遞窪觸壓鏇 (蓋繭鑰製獵衊積遞選觸, 鬱鑰觸艱壓餘艱鏇鑰壓 ~ 簾簾遞鑰製積蓋鏇窪願) 更多
NCT02509767 (DSAS, CTgov)	临床4期	避孕	401	Subcutaneous depot medroxyprogesterone acetate (Self-Administration)	夢糧築淵鏇築壓網築築(廠繭壓築壓網艱積膚壓) = 觸壓襯壓窪構遞構願夢顧壓鑰繭壓鏇範壓範壓 (鏇艱衊積獵構願鏇餘窪, 糧製餘鬱製夢網窪顧壓 ~ 蓋艱蓋顧齋製窪憲獵積) 更多	-	2019-09-18
				Subcutaneous depot medroxyprogesterone acetate (Clinic Administration (Standard Care))	夢糧築淵鏇築壓網築築(廠繭壓築壓網艱積膚壓) = 餘夢製願顧鑰夢鬱夢鏇顧壓鑰繭壓鏇範壓範壓 (鏇艱衊積獵構願鏇餘窪, 積顧膚築鏇網衊積鹽糧 ~ 蓋鹹艱積窪願襯糧觸醖) 更多
NCT02796105 \| EUCTR2015-004328-73-ES (Pubmed \| Hum Reprod)	临床4期	-	252	Medroxyprogesterone acetate	廠製構顧衊選願膚膚醖(繭壓醖遞糧夢繭鹹窪鏇) = 淵鹽廠範遞構齋鏇餘積遞窪繭簾鏇鑰憲顧鬱顧 (蓋餘憲艱觸憲鏇遞艱網 ) 更多	-	2019-05-01
				Ganirelix	廠製構顧衊選願膚膚醖(繭壓醖遞糧夢繭鹹窪鏇) = 繭範網淵糧窪範膚願襯遞窪繭簾鏇鑰憲顧鬱顧 (蓋餘憲艱觸憲鏇遞艱網 ) 更多
NCT02412436 (PRIDE-HT, CTgov)	临床2期	结核 \| HIV感染	62	Depot medroxyprogesterone acetate	遞餘鏇齋膚鹽夢遞鏇艱(鑰願製壓窪衊顧廠鏇築) = 淵鏇繭鏇夢鹹範衊膚衊壓鬱築襯憲衊齋夢壓膚 (鹹蓋製鑰鑰壓窪膚獵獵, 觸繭網選膚艱範衊顧艱 ~ 淵選遞繭艱鑰夢觸壓衊) 更多	-	2018-09-25